Literature DB >> 9399333

Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.

O V Olesen1, K Linnet.   

Abstract

The metabolism of amitriptyline was studied in vitro using cDNA-expressed human cytochrome P450 (CYP) enzymes 1A2, 3A4, 2C9, 2C19, 2D6 and 2E1. CYP 2C19 was the most important enzyme with regard to the demethylation of amitriptyline, the quantitatively most important metabolic pathway. CYP 1A2, 3A4, 2C9 and CYP 2D6 also participated in the demethylation of amitriptyline. CYP 2D6 was the sole enzyme mediating the hydroxylation of amitriptyline, and (E)-10-OH-amitriptyline was exclusively produced. CYP 2E1 did not metabolize amitriptyline. Concerning the quantitative relations, CYP 2C19 and 2D6 exhibited high affinities with Km values in the range of 5-13 mumol/l, whereas the affinities of 1A2, 3A4 and 2C9 were somewhat lower with Km values ranging from 74 to 92 mumol/l. CYP 2C19 displayed the highest reaction capacity per mole with Vmax equal to 475 mol h-1 (mol CYP)-1. The other enzymes had Vmax values in the range of 90-145 mol h-1 (mol CYP)-1. Allowing for the typical relative distribution of amounts of CYP enzymes in the liver, a simulation study suggested that, at therapeutic doses, on average about 60% of the metabolism depended on CYP 2C19. At toxic doses, CYP 2C19 is expected to be saturated, and CYP 3A4 may now play a dominant role in the metabolism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399333     DOI: 10.1159/000139533

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  15 in total

1.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

Review 4.  Monotherapy or combination therapy for fibromyalgia treatment?

Authors:  Elena Pita Calandre; Fernando Rico-Villademoros; Carmen María Rodríguez-López
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

5.  Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity.

Authors:  Jennifer Cohen Smith; Steven C Curry
Journal:  J Med Toxicol       Date:  2011-09

Review 6.  Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome.

Authors:  Grace Ewing; Yekaterina Tatarchuk; Dina Appleby; Nadav Schwartz; Deborah Kim
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

7.  Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans.

Authors:  Shimpei Watanabe; Unnikrishnan Kuzhiumparambil; My Ann Nguyen; Jane Cameron; Shanlin Fu
Journal:  AAPS J       Date:  2017-04-28       Impact factor: 4.009

Review 8.  Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.

Authors:  Farzin Zobdeh; Ivan I Eremenko; Mikail A Akan; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

9.  Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literature.

Authors:  Lampros Samartzis; Paraskevi Savvari; Sofoklis Kontogiannis; Stavros Dimopoulos
Journal:  Case Rep Psychiatry       Date:  2013-03-04

10.  Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline.

Authors:  A Bruce Janati; Naif Alghasab; Aboubaker Osman
Journal:  Case Rep Neurol Med       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.